Patient-Derived Xenografts of Triple-Negative Breast Cancer Enable Deconvolution and Prediction of Chemotherapy Responses

Enregistré dans:

Détails bibliographiques
Publié dans:	bioRxiv (Dec 12, 2024)
Auteur principal:	Lei, Jonathan T
Autres auteurs:	Dobrolecki, Lacey E, Huang, Chen, Srinivasan, Ramakrishnan R, Vasaikar, Suhas V, Lewis, Alaina N, Sallas, Christina, Zhao, Na, Cao, Jin, Landua, John D, Chang In Moon, Liao, Yuxing, Hilsenbeck, Susan G, Osborne, C Kent, Rimawi, Mothaffar F, Ellis, Matthew J, Petrosyan, Varduhi, Wen, Bo, Li, Kai, Saltzman, Alexander B, Jain, Antrix, Malovannaya, Anna, Wulf, Gerburg M, Marangoni, Elisabetta, Li, Shunqiang, Kraushaar, Daniel C, Wang, Tao, Damodaran, Senthil, Zheng, Xiaofeng, Meric-Bernstam, Funda, Echeverria, Gloria V, Meenakshi Anurag, Chen, Xi, Welm, Bryan E, Welm, Alana L, Zhang, Bing, Lewis, Michael T
Publié:	Cold Spring Harbor Laboratory Press
Sujets:	AstraZeneca AbbVie Inc Pfizer Inc Envigo Seattle Genetics Inc Antagonism Models Experimental research Cancer therapies Cytokeratin Biotechnology Oncology Disease management Breast cancer Transcriptomics Proteomics Royalties Histone deacetylase Stockholders Biomarkers Research funding Licenses Carboplatin Chemotherapy Patients Chemoresistance Fees & charges Xenografts
Accès en ligne:	Citation/Abstract Full Text - PDF Full text outside of ProQuest
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Soyez le premier à ajouter un commentaire!